Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
98 hedge funds and large institutions have $556M invested in Revance Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 40 increasing their positions, 17 reducing their positions, and 3 closing their positions.
1,100% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 3
135% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 17
49% more capital invested
Capital invested by funds: $373M → $556M (+$183M)
48% more funds holding
Funds holding: 66 → 98 (+32)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$29.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$21.9M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$13M |
| 4 |
JP Morgan Chase
New York
|
+$12.7M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$11.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VAM
Visium Asset Management
New York
|
-$16.8M |
| 2 |
ZDA
Zweig-DiMenna Associates
New York
|
-$6.41M |
| 3 |
Millennium Management
New York
|
-$6.29M |
| 4 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$4.67M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$2.66M |
RVNC Hedge Fund Activity: Q2 2014 in Review
98 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2014, worth a combined $556M — up 49% from $373M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new RVNC positions and 3 closed out — a net gain of 33 holders — while 40 added to existing stakes and 17 trimmed.
The largest buyer was Jennison Associates, adding an estimated $29.6M. The largest seller was Visium Asset Management, cutting an estimated $16.8M.
- 98 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2014, up from 66 in Q1 2014.
- Funds reported $556M of Revance Therapeutics, Inc. stock for Q2 2014, up 49% quarter-over-quarter.
- 36 funds opened new Revance Therapeutics, Inc. positions in Q2 2014 and 3 closed out, a net change of +33 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2014 was Jennison Associates, an estimated $29.6M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2014 was Visium Asset Management, an estimated $16.8M sold.
Based on aggregated 13F filings for Q2 2014.